Posts by Sandra Ansanay-Alex
PeriVision, Bioscibex and Carewell receive support from FIT
Perivision and its software combining artificial intelligence and complex algorithms to carry out vision examinations, Bioscibex and its innovative bioreactor for drug production, and Carewell and its platform connecting the needs of health and care facilities with available qualified personnel. All three received support from FIT via a Tech Growth loan of CHF 300,000, a…
Read MoreSwiss Medtech Award 2025
evismo, QUMEA, and Bonebridge have reached the finals for the renowned Swiss Medtech Award 2025. The three companies will compete for a chance to win this prestigious honour recognising innovation and entrepreneurial excellence in the Swiss medtech sector. The winner of CHF 50,000 and the coveted trophy will be announced on 25 June during Swiss…
Read MoreBeech Biotech Secures €500,000 Grant
Lausanne-based startup Beech Biotech has been awarded €500,000 through the BioInnovation Institute (BII) Venture Lab programme to accelerate the development of a novel placenta-impermeable antibody aimed at treating preeclampsia, a life-threatening pregnancy complication. Addressing a Critical Unmet Medical Need Preeclampsia remains a major global health challenge, affecting millions of pregnancies each year. The condition,…
Read MoreFuture of Health Grant (FoHG) – Spring Batch
Future of Health Grant (FoHG) selected six innovative startups for its spring batch. Switzerland’s digital health transformation is gaining momentum, as seen in the record-breaking 243 applications received by the Future of Health Grant (FoHG) for its Spring Batch. This program, backed by CSS Insurance and the EPFL Innovation Park, supports startups in digital health.…
Read MoreGeneva Unveils Master Plan To Become An Innovation Hub
The State of Geneva has unveiled an ambitious master plan aimed at transforming the canton into a global innovation hub. In addition to the CHF 10 million already invested annually in the sector, an extra CHF 11 million will be injected over the next three years, until 2027. Unveiled at Campus Biotech by State Councilor…
Read MoreCSEM receives a CHF 3 Million Funding from Canton of Neuchâtel
The Canton of Neuchâtel has announced a strategic initiative to support the semiconductor industry, recognizing its pivotal role in technological innovation and economic growth. As part of this plan, the Swiss Center for Electronics and Microtechnology (CSEM) will receive CHF 3 million in innovation funding between 2024 and 2028, enabling it to modernize its equipment…
Read MorePhilippe Renevey Wins CSEM Inventor Award 2025
More than two decades after CSEM pioneered wrist-based pulse monitoring, engineer Philippe Renevey is being honored with the CSEM Inventor Award 2025 for his revolutionary PulseSpeed patent. This breakthrough innovation enables high-precision heart rate measurement, opening new possibilities for wearable health technology. The Science Behind PulseSpeed Whether jogging, climbing stairs, or simply walking, smartwatches…
Read MoreDebiotech : Pioneering Medical Device Innovation since 35 Years
2025 marks a significant milestone for Debiotech as it celebrates 35 years of innovation in medical device development. The Vaud-based company also recently evolved into a contract engineering company. In 2025, Debiotech proudly celebrates 35 years of pioneering innovations in the medical device sector. With an outstanding legacy of excellence in designing advanced drug…
Read MoreHello Tomorrow
Hello Tomorrow Global Summit is a Deep Take event taking place from 11 to 12 June 2026 in Amsterdam Hello Tomorrow is a global initiative that connects high-tech entrepreneurs with companies and investors, and provides consulting services in strategy and innovation. The event attracts more than 4,000 participants, 100 speakers, 125 exhibitors and dozens…
Read MoreAB2 Bio & Nippon Shinyaku Partner on U.S. License for Tadekinig Alfa
AB2 Bio and Nippon Shinyaku Sign U.S. Licensing Agreement for Tadekinig Alfa to Treat Ultra-Rare Autoimmune Disease AB2 Bio Ltd., a Vaud-based biotech company specializing in therapies for severe hyperinflammatory diseases, has entered into a strategic agreement with Nippon Shinyaku, a leading Japanese pharmaceutical company, for the commercialization of its breakthrough treatment Tadekinig alfa…
Read More